Researchers found that the overexpression of IFI6 under the influence of the activator of HSP90AA1 ATPase Activity 1 (AHSA1)-HSP90AA1 complex significantly enhanced osimertinib resistance in epidermal growth factor receptor (EGFR)-mutated LUAD cells.
[Cell Death & Disease]